Annovis Bio, Inc. (ANVS) stock
ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.93+0.08 (+9.31%)
Close on Nov 13, 2026Market cap $39.46MP/E –Yield –
Annovis Bio cash
Cash and short-term investments held at the end of each period.
Annovis Bio's cash was $2.82M at Sep 30, 2026. For fiscal 2025 it was $19.53M, up 85.1% from the year before. The highest annual figure on record is $45.69M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.53M | +85.1% |
| FY2024 | Dec 31, 2024 | $10.55M | +83.4% |
| FY2023 | Dec 31, 2023 | $5.75M | -79.7% |
| FY2022 | Dec 31, 2022 | $28.38M | -37.9% |
| FY2021 | Dec 31, 2021 | $45.69M | +465.8% |
| FY2020 | Dec 31, 2020 | $8.07M | +434488.7% |
| FY2019 | Dec 31, 2019 | $1.86K | -94.7% |
| FY2018 | Dec 31, 2018 | $35.31K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.82M | -81.6% |
| Q2 FY2026 | Jun 30, 2026 | $18.73M | +9.3% |
| Q1 FY2026 | Mar 31, 2026 | $14.22M | -36.1% |
| Q4 FY2025 | Dec 31, 2025 | $19.53M | +85.1% |
| Q3 FY2025 | Sep 30, 2025 | $15.29M | +21.0% |
| Q2 FY2025 | Jun 30, 2025 | $17.13M | +328.5% |
| Q1 FY2025 | Mar 31, 2025 | $22.24M | +608.8% |
| Q4 FY2024 | Dec 31, 2024 | $10.55M | +83.4% |
| Q3 FY2024 | Sep 30, 2024 | $12.64M | +98.8% |
| Q2 FY2024 | Jun 30, 2024 | $4.00M | -74.6% |
| Q1 FY2024 | Mar 31, 2024 | $3.14M | -81.3% |
| Q4 FY2023 | Dec 31, 2023 | $5.75M | -79.7% |
| Q3 FY2023 | Sep 30, 2023 | $6.35M | -80.1% |
| Q2 FY2023 | Jun 30, 2023 | $15.72M | -56.3% |
| Q1 FY2023 | Mar 31, 2023 | $16.76M | -60.7% |
| Q4 FY2022 | Dec 31, 2022 | $28.38M | -37.9% |
| Q3 FY2022 | Sep 30, 2022 | $31.99M | -32.6% |
| Q2 FY2022 | Jun 30, 2022 | $35.97M | -26.9% |
| Q1 FY2022 | Mar 31, 2022 | $42.67M | +661.6% |
| Q4 FY2021 | Dec 31, 2021 | $45.69M | +465.8% |
| Q3 FY2021 | Sep 30, 2021 | $47.46M | +436.8% |
| Q2 FY2021 | Jun 30, 2021 | $49.22M | +404.2% |
| Q1 FY2021 | Mar 31, 2021 | $5.60M | -49.6% |
| Q4 FY2020 | Dec 31, 2020 | $8.07M | +434488.7% |
| Q3 FY2020 | Sep 30, 2020 | $8.84M | +15616.6% |
| Q2 FY2020 | Jun 30, 2020 | $9.76M | +9238.3% |
| Q1 FY2020 | Mar 31, 2020 | $11.12M | +3204.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.86K | -94.7% |
| Q3 FY2019 | Sep 30, 2019 | $56.25K | – |
| Q2 FY2019 | Jun 30, 2019 | $104.55K | – |
| Q1 FY2019 | Mar 31, 2019 | $336.57K | – |
| Q4 FY2018 | Dec 31, 2018 | $35.31K | – |
See a number that looks wrong?